Research & Development
Relief Therapeutics seeks US FDA emergency approval for its drug against COVID-19
23 September 2020 -

Swiss drug development company Relief Therapeutics Holdings SA (Relief Therapeutics)(SWX:RLF) said on 23 September 2020 that along with its US partner NeuroRx, it has asked the US Food and Drug Administration for emergency approval for a drug it aims to repurpose against COVID-19, Reuters news agency reported on Wednesday.

Citing a 51-person study, Relief Therapeutics said in a statement: "Patients treated with RLF-100 demonstrated a three-fold advantage in survival, recovery from respiratory failure and other parameters indicative of meaningful clinical improvement."

The company added that the request, if granted, would make the drug, previously used against conditions including erectile dysfunction, available to those in intensive care who have exhausted all approved treatments.



Related Headlines